Q-omics provides the consensus-scored ANKRD46 profile across patient tissues and cancer cell-line models. ANKRD46 expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, ANKRD46 is differentially expressed in 11, with the highest sampling consensus in THCA. Additionally, ANKRD46 RNA expression shows 20,588 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight KIRC, THCA, and UVM as cancer lineages where ANKRD46 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ANKRD46 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ANKRD46 survival associations across molecular data types. ANKRD46 RNA expression shows survival associations in the most cancer types (25), followed by mutation status (2) and mass-spec protein abundance (3). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ANKRD46 RNA expression–survival associations across cancer types. High ANKRD46 expression shows unfavorable associations in UVM, KIRP and SCLC, but favorable associations in KIRC, LGG and LUAD. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for ANKRD46 RNA expression.
This table summarizes ANKRD46 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11, while mass-spec protein shows differences in 4. The strongest signals are observed in THCA for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for ANKRD46. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ANKRD46 shows lower tumor expression in THCA, KIRP, KIRC, KICH and LUAD and higher tumor expression in HNSC. The THCA box plot shows higher ANKRD46 RNA expression in normal versus tumor tissue (log2 FC = −1.504, t-test p < 0.001).
This table shows molecular features associated with ANKRD46 in patient tissues and cancer cell lines. In patient samples, ANKRD46 shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, ANKRD46 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in SKIN, while CRISPR and shRNA rows add functional-dependency signals in LUNG_SCLC and BLOOD_Lymphoma.
